Mynosys Cellular Devices has announced that its flagship automated capsulotomy device, »Zepto, has been selected as the best capsulotomy technology by Cataract and Refractive Surgery Today.
“The ability to create quick and reliable capsulotomies, even in dense lenses with limited visibility, is an attractive feature of this promising technology,” Chief Medical Editor of CRST, Steven J. Dell, MD, of Austin, Texas, said.
Editorial board member Vance Thompson, MD, of Sioux Falls, South Dakota, called Zepto “amazing.”
“This technology allows cataract surgeons to automatically create a perfectly circular capsulotomy that for the first time can be precisely centered on the patient’s visual axis to anchor surgery for potentially the best outcome,” Dr. Thompson said.
Zepto has received an extremely enthusiastic welcome by cataract surgeons, according to John Hendrick, President & CEO of Mynosys.
“Since its international launch in early 2017 and in the US in October 2017, Zepto has very quickly established itself to be the ‘go to’ instrument in challenging cases, and is also increasingly used by surgeons to perform personalized cataract procedures whereby a Zepto-guided, visually centered capsulotomy can anchor the surgery to the patient’s individual visual axis,” Mr. Hendrick said. “The feedback from surgeons, no matter in hospital-based settings or in high volume premium practices has uniformly been: ‘Accuracy & strength at another level,’ ‘a feeling of achievement,’ ‘increases my efficiency,’ and ‘wow.’
Zepto is CE Marked and FDA cleared. It is available through distributors in selected countries internationally and in the United States.